Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Development and Validation of a Salivary Tau Biomarker in Alzheimer Disease
FY 2014-15
Summary
Once the development of an effective therapy for Alzheimer's disease (AD) is established, the existence of a reliable and easily accessible early biomarker for the disease will be crucial. Previous work has established CSF levels of amyloid beta and tau as biomarkers. However, lumbar punctures are invasive and expensive. The objective of our project, which is based on preliminary data, is to determine if salivary tau can be used as sensitive and reliable biomarker for AD and if it has sensitivity to detect levels in mild cognitive impairment (MCI) patients. Through a purification technique and a western-dot-blot assay, we will be able to determine the level and composition of salivary tau. We will determine if the biomarker has acceptable specificity and sensitivity in subjects with mild AD compared to age-matched controls and other neurological disease patients, such as frontotemporal dementia and stroke. We will also assess salivary tau levels in subjects with MCI, and see whether the levels correlate with measures of cognition and hippocampal volumes. If salivary tau is determined to be a reliable biomarker for MCI/early AD, then we will be able to more easily and readily identify those who would be the best candidates for early treatment.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
331299
Name
Pekeles Heather
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Development and Validation of a Salivary Tau Biomarker in Alzheimer Disease
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alzheimer'S Disease; Biomarkers; Dementia; Mild Cognitive Impairment; Saliva; Tau Protein
Abstract
Once the development of an effective therapy for Alzheimer's disease (AD) is established, the existence of a reliable and easily accessible early biomarker for the disease will be crucial. Previous work has established CSF levels of amyloid beta and tau as biomarkers. However, lumbar punctures are invasive and expensive. The objective of our project, which is based on preliminary data, is to determine if salivary tau can be used as sensitive and reliable biomarker for AD and if it has sensitivity to detect levels in mild cognitive impairment (MCI) patients. Through a purification technique and a western-dot-blot assay, we will be able to determine the level and composition of salivary tau. We will determine if the biomarker has acceptable specificity and sensitivity in subjects with mild AD compared to age-matched controls and other neurological disease patients, such as frontotemporal dementia and stroke. We will also assess salivary tau levels in subjects with MCI, and see whether the levels correlate with measures of cognition and hippocampal volumes. If salivary tau is determined to be a reliable biomarker for MCI/early AD, then we will be able to more easily and readily identify those who would be the best candidates for early treatment.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pekeles, Heather
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~